UNC2025 2HCl

CAS No. ——

UNC2025 2HCl ( —— )

Catalog No. M17708 CAS No. ——

UNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 101 Get Quote
10MG 172 Get Quote
25MG 333 Get Quote
50MG 587 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    UNC2025 2HCl
  • Note
    Research use only, not for human use.
  • Brief Description
    UNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.
  • Description
    UNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    PARP
  • Recptor
    Mer|Flt3
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    549.62
  • Molecular Formula
    C28H42Cl2N6O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Cl.Cl.OC1CCC(CC1)n3cc(c2cnc(NCCCC)nc23)c4ccc(cc4)CN5CCN(C)CC5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Zhang W,etal.UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.J Med Chem. 2014 Aug 28;57(16):7031-41.
molnova catalog
related products
  • Senaparib

    Senaparib is a novel highly potent and selective oral PARP1/2 inhibitor with strong antitumor activity.

  • PARP10-IN-3

    PARP10-IN-3 is a potent and selective mono-Adp-ribotransferase PARP10 inhibitor that inhibits human PARP10 (IC50:480 nM). PARP10-IN-3 also inhibited human PARP2 and human PARP15 with IC50 values of 1.7 μM.

  • Fluzoparib

    fluzoparib is a novel, potent, and orally available inhibitor of PARP, potentially for the treatment of solid tumours.Fluzoparib potently inhibited PARP1 enzyme activity and induced DNA double-strand breaks, G2 /M arrest, and apoptosis in homologous recombination repair (HR)-deficient cells.?